Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification $25.9 million in cash and cash equivalents as of June 30, 2024; cash runway into the third quarter of 2025 FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to a ...

FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it received written notification from The Nasdaq Stock Market LLC ("Nasdaq") that it has granted the Company's request for a 180-day extension to regain compliance with the continued listing requirements for The Nasda ...

FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that it has granted the Company’s request for a 180-day extension to regain compliance with the continued listing requirements for The Nasd ...

合作伙伴关系 - Apollomics的合作伙伴Avistone获得中国国家药品监督管理局批准，将vebreltinib用于治疗带有PTPRZ1-MET融合基因的胶质瘤[1] 全球首个获批药物 - vebreltinib成为全球首个获批用于治疗带有c-Met改变的中枢神经系统肿瘤的c-Met抑制剂[2] 临床研究结果 - vebreltinib在中国获批治疗ZM融合阳性胶质瘤的批准基于Avistone的FUGEN研究结果，显示其在患者中显著提高生存率[5]

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, presented two posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting, held April 5-10, 2024 in San Diego, Calif. Copies of the posters are available on the Apollomics website at ir.apollomicsinc.com/news-events/presentations. "Vebreltinib's selectivity and high in vivo potenc ...

公司财务状况 - 公司截至2022年6月30日的现金及现金等价物为61,696千美元[29] - 公司总资本为95,524千美元[29] 公司股权结构 - 公司执行董事和高管持有公司普通股的比例分别为6.2%和4.6%[49] - OrbiMed Advisors LLC持有公司普通股的比例为10.5%[49] - MP One Investment LLC持有公司普通股的比例为54.1%[49] 公司股票信息 - 公司普通股和认股权证分别在纳斯达克上市，代码分别为“APLM”和“APLMW”[58] - 公司普通股和认股权证的持有人应获取其证券的最新市场报价[58] - 公司的股本为650,000,000股，其中包括500,000,000股Apollomics A类普通股，100,000,000股Apollomics B类普通股和50,000,000股优先股[69] - 公司的Warrants数量为10,969,400，每张Warrant可以以11.50美元的价格购买一股A类普通股[62] - Penny Warrants将在Closing Date后六个月开始行使，五年后到期，届时将自动以现金方式行使[63]

Apollomics, Inc. (NASDAQ:APLM) Q4 2023 Earnings Conference Call March 28, 2024 8:00 AM ET Company Participants Guo Liang Yu - Chairman and Chief Executive Officer Sanjeev Redkar - Co-founder, Executive Director and President Matthew Plunkett - Chief Financial Officer Conference Call Participants Tim Moore - EF Hutton Operator Good morning ladies and gentlemen. Welcome to the Apollomics Full Year 2023 Results Conference Call. Before we begin, we want to advise you that over the course of the call and questio ...

Exhibit 99.1 Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results • Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling program • Completed patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025 • $37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025 • Management to host conferenc ...

FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics. "It's our pleasure to welcome Matt to the Apollomics team. We expect his financial strategy and business development expertise from working with development and commercial stage public companies to ...

FOSTER CITY, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) (the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on January 16, 2024, it received a notification (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the ...